切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2020, Vol. 14 ›› Issue (01) : 5 -9. doi: 10.3877/cma.j.issn.1674-0793.2020.01.003

所属专题: 文献

论著

长链非编码RNA牛磺酸调节基因1和miR-132的表达与乳腺癌预后的关系
卢小冬1,()   
  1. 1. 226500 南通,江苏省如皋市人民医院普外科
  • 收稿日期:2018-08-22 出版日期:2020-02-01
  • 通信作者: 卢小冬

Expression of long non-coding RNA taurine upregulated gene 1 and miR-132 in breast cancer andtheir relationship with prognosis

Xiaodong Lu1,()   

  1. 1. Department of General Surgery, Rugao People’s Hospital, Jiangsu Province, Nantong 226500, China
  • Received:2018-08-22 Published:2020-02-01
  • Corresponding author: Xiaodong Lu
  • About author:
    Corresponding author: Lu Xiaodong, Email:
引用本文:

卢小冬. 长链非编码RNA牛磺酸调节基因1和miR-132的表达与乳腺癌预后的关系[J/OL]. 中华普通外科学文献(电子版), 2020, 14(01): 5-9.

Xiaodong Lu. Expression of long non-coding RNA taurine upregulated gene 1 and miR-132 in breast cancer andtheir relationship with prognosis[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(01): 5-9.

目的

探讨乳腺癌中长链非编码RNA(LncRNA)牛磺酸调节基因(TUG)1和miR-132表达情况及两者表达水平与患者预后的关系。

方法

收集2014年1月至2017年11月如皋市人民医院90例手术切除的乳腺癌组织和相应癌旁组织,采用qRT-PCR法检测TUG1和miR-132表达水平,使用Kaplan-Meier法计算TUG1和miR-132表达对乳腺癌患者生存率的影响,采用Cox回归模型分析乳腺癌预后的影响因素。

结果

与癌旁组织相比,乳腺癌组织中TUG1表达水平明显升高(t=65.781,P<0.001),miR-132表达水平显著下降(t=33.089,P<0.001),均与雌激素受体(ER)、人表皮生长因子受体2(HER-2)、FIGO分期、分化程度和淋巴结转移相关(均P<0.05)。乳腺癌组织中TUG1和miR-132表达之间呈负相关关系(r=-0.767,P=0.025)。TUG1高表达者3年生存率为80.77%(42/52),显著低于低表达者97.37%(37/38)(χ2=5.639,P=0.018);miR-132低表达者3年生存率为81.25%(39/48),显著低于高表达者95.24%(40/42)(χ2=4.085,P=0.043)。Cox回归分析发现,ER、HER-2、FIGO分期、分化程度、淋巴结转移、TUG1和miR-132均是乳腺癌患者预后的影响因素(均P<0.05)。

结论

在乳腺癌组织中,TUG1表达水平显著上调,miR-132表达水平显著下调,且两者呈负相关,都是影响预后的独立因素。TUG1可能通过调控miR-132的表达发挥促癌基因的作用,有望成为乳腺癌独立预后标志物和治疗新靶点。

Objective

To investigate the expression of long non-coding (Lnc) RNA taurine upregulated gene (TUG) 1 and microRNA (miR)-132 in breast cancer and their relationship with prognosis.

Methods

Ninety cases of surgically resected breast cancer tissues and the corresponding paracancerous tissue were collected in Rugao People’s Hospital from January 2014 to November 2017. The expression levels of TUG1 and miR-132 were detected by qRT-PCR, effect of TUG1 and miR-132 expression on survival rate of breast cancer patients using Kaplan-Meier method, and analysis of prognostic factors of breast cancer by Cox regression model.

Results

Compared with the adjacent tissues, the expression of TUG1 increased significantly (t=65.781, P<0.001), while the expression of miR-132 decreased significantly (t=33.089, P<0.001). The up-regulation of TUG1 and the down-regulation of miR-132 expression was correlated with ER, HER-2, FIGO stage, differentiation degree and lymph node metastasis (all P<0.05). There was a significantly negative correlation between the expression of TUG1 and miR-132 in breast cancer tissues (r=-0.767, P=0.025). The 3-year survival rate of patients with high expression of TUG1 was 80.77% (42/52), significantly lower than 97.37% (37/38) of those with low expression of microRNAs (χ2=5.639, P=0.018), and 81.25% (39/48) of those with low expression of miR-132, significantly lower than 95.24% (40/42) of those with high expression of microRNAs (χ2=4.085, P=0.043). Cox regression analysis showed that ER, HER-2, FIGO staging, differentiation, lymph node metastasis, TUG1 and miR-132 were independent prognostic factors for breast cancer patients (all P<0.05).

Conclusions

TUG1 expression is significantly up-regulated and miR-132 expression is significantly down-regulated in breast cancer tissues, both of which are negatively correlated and independent prognostic factors. TUG1 may play an oncogene role by regulating the expression of miR-132, and may become an independent prognostic marker and a new therapeutic target for breast cancer.

表1 GAPDH、TUG1、U6和miR-132引物序列
表2 TUG1和miR-132在乳腺癌组织和癌旁组织中的表达(±s
表3 TUG1和miR-132表达与乳腺癌临床病理特征的关系[例(%)]
图2 TUG1和miR-132不同表达的乳腺癌患者生存曲线 A为TUG1高表达对乳腺癌患者生存影响;B为miR-132低表达对乳腺癌患者生存影响
表4 影响乳腺癌预后的多因素分析
[1]
王莹,辛彦. Hippo通路和相关长链非编码RNA(LncRNA)与肿瘤关系的研究进展[J]. 现代肿瘤医学, 2015, 23(21): 3190-3193.
[2]
Zhang EB, Yin DD, Sun M, et al. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression[J]. Cell Death Dis, 2014, 5: e1243.
[3]
Sun J, Ding C, Yang Z, et al. The long non-coding RNA TUG1 indicates a poor prognosis for colorectal cancer and promotes metastasis by affecting epithelial-mesenchymal transition[J]. J Transl Med, 2016, 14(1): 42-47.
[4]
Zhang E, He X, Yin D, et al. Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57[J]. Cell Death Dis, 2016, 7: e2109.
[5]
邢智伟,苏秀兰. 微小RNA和肿瘤治疗的研究进展[J]. 中国医药导报, 2017, 14(3): 27-30.
[6]
Formosa A, Lena AM, Markert EK, et al. DNA methylation silences miR-132 in prostate cancer[J]. Oncogene, 2013, 32(1): 127-134.
[7]
沙敏,王变,肖丽, 等. miR-212/132在原发性肝癌患者血清中的表达及其对高尔基体糖蛋白73的靶向调控[J]. 中华肝脏病杂志, 2017, 25(12): 920-926.
[8]
Liu X, Yu H, Cai H, et al. The expression and clinical significance of miR-132 in gastric cancer patients[J]. Diagn Pathol, 2014, 9(1): 57.
[9]
应靖,赵益,孙有智. 中医药治疗乳腺癌主要术后并发症的进展[J]. 江西中医药, 2018, 49(7): 70-72.
[10]
Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: A new frontier of translational research?[J]. Oncogene, 2012, 31(43): 4577-4587.
[11]
朱玉翠,张晓彤,周亚男, 等. 长链非编码RNA TUG1在肝细胞癌中的生物信息学分析[J]. 国际检验医学杂志, 2018, 39(10): 1153-1162.
[12]
韩鹦赢,沈鹏. 长链非编码核糖核酸牛磺酸上调基因1在肺腺癌中的表达及生物学意义研究[J]. 中国现代医学杂志, 2017, 27(7): 41-45.
[13]
Li T, Liu Y, Xiao H, et al. Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer[J]. Breast Cancer, 2016, 24(4): 535-543.
[14]
赵继明,彭健. Micro RNA-132对结肠癌细胞生物学功能的作用[J]. 中国现代医学, 2016, 26(1): 30-34.
[15]
杨波,李胜泽,马玲, 等. miR-132靶向调控Ezrin抑制卵巢癌细胞增殖、促进凋亡的实验研究[J]. 中国免疫学杂志, 2017, 33(1): 72-75.
[16]
管娣,刘春颖,陈晨, 等. MiR-132抑制肿瘤转移[J]. 生物化学与生物物理进展, 2013, 40(2): 159-164.
[17]
Zhu J, Shi H, Liu H, et al. Long non-coding RNA TUG1 promotes cervical cancer progression by regulating the miR-138-5p-SIRT1 axis[J]. Oncotarget, 2017, 8(39): 65253-65264.
[18]
Li G, Liu K, Du X. Long non-coding RNA TUG1 promotes proliferation and inhibits apoptosis of osteosarcoma cells by sponging miR-132-3p and upregulating SOX4 expression[J]. Yonsei Medl J, 2018, 59(2): 226-235.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
阅读次数
全文


摘要